Literature DB >> 32173274

"You are not clean until you're not on anything": Perceptions of medication-assisted treatment in rural Appalachia.

Emma L Richard1, Christine A Schalkoff2, Hannah M Piscalko3, Daniel L Brook3, Adams L Sibley2, Kathryn E Lancaster3, William C Miller3, Vivian F Go2.   

Abstract

BACKGROUND: Medication-assisted treatment (MAT) is an evidence-based strategy to treat opioid use disorder (OUD). However, MAT-related stigma reduces MAT uptake, which is particularly low in rural areas. To date, perceptions and attitudes towards MAT in rural settings have not been described.
OBJECTIVE: This qualitative study aims to characterize perceptions and attitudes towards MAT and the environmental factors contributing to these views in Appalachian Ohio.
METHODS: From February to July 2018, semi-structured interviews were conducted with 34 stakeholders (12 healthcare professionals, 12 substance use treatment providers, 7 law enforcement agents and judicial officials, and 3 members of relevant organizations) in three rural counties in Appalachian Ohio. Interviews were transcribed, coded, and analyzed to characterize the risk environment and participants' perceptions and attitudes towards MAT.
RESULTS: Participants expressed or described pervasive MAT-related stigma in the region. Participants consistently described three elements of the environment affecting stigma: (1) a "conservative" culture in which abstinence is necessary to be in recovery successfully, (2) fear of medication diversion and abuse, and (3) drug court policies that keep MAT out of the criminal justice system.
CONCLUSION: MAT-related stigma will need to be addressed to tackle the opioid epidemic through evidence-based treatment effectively.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Appalachia; Medication-assisted treatment; Opioid use disorder; Risk environment; Rural; Stigma

Year:  2020        PMID: 32173274      PMCID: PMC8018539          DOI: 10.1016/j.drugpo.2020.102704

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  39 in total

1.  National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

Authors:  Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz
Journal:  Am J Public Health       Date:  2015-06-11       Impact factor: 9.308

2.  Utilization of drug treatment programs by methamphetamine users: the role of social stigma.

Authors:  Shirley J Semple; Igor Grant; Thomas L Patterson
Journal:  Am J Addict       Date:  2005 Jul-Sep

3.  Perceptions and practices addressing diversion among US buprenorphine prescribers.

Authors:  Lewei Allison Lin; Michelle R Lofwall; Sharon L Walsh; Adam J Gordon; Hannah K Knudsen
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

4.  Stigma from the Viewpoint of the Patient.

Authors:  Joycelyn Sue Woods; Herman Joseph
Journal:  J Addict Dis       Date:  2015

5.  Why aren't physicians prescribing more buprenorphine?

Authors:  Andrew S Huhn; Kelly E Dunn
Journal:  J Subst Abuse Treat       Date:  2017-04-12

Review 6.  Methadone maintenance treatment (MMT): a review of historical and clinical issues.

Authors:  H Joseph; S Stancliff; J Langrod
Journal:  Mt Sinai J Med       Date:  2000 Oct-Nov

7.  The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.

Authors:  Bradley D Stein; Adam J Gordon; Mark Sorbero; Andrew W Dick; James Schuster; Carrie Farmer
Journal:  Drug Alcohol Depend       Date:  2011-11-16       Impact factor: 4.492

8.  Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.

Authors:  Robert P Schwartz; Jan Gryczynski; Kevin E O'Grady; Joshua M Sharfstein; Gregory Warren; Yngvild Olsen; Shannon G Mitchell; Jerome H Jaffe
Journal:  Am J Public Health       Date:  2013-03-14       Impact factor: 9.308

Review 9.  Biogenetic explanations and stigma: a meta-analytic review of associations among laypeople.

Authors:  Erlend P Kvaale; William H Gottdiener; Nick Haslam
Journal:  Soc Sci Med       Date:  2013-07-31       Impact factor: 4.634

10.  Clinician beliefs and attitudes about buprenorphine/naloxone diversion.

Authors:  Zev Schuman-Olivier; Hilary Connery; Margaret L Griffin; Steve A Wyatt; Alan A Wartenberg; Jacob Borodovsky; John A Renner; Roger D Weiss
Journal:  Am J Addict       Date:  2013-04-11
View more
  11 in total

1.  The Broken Care Continuum for Young Adults With Opioid Addiction.

Authors:  Scott E Hadland
Journal:  J Adolesc Health       Date:  2020-12       Impact factor: 5.012

2.  Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities.

Authors:  Emily Pasman; Rachel Kollin; Michael Broman; Guijin Lee; Elizabeth Agius; Jamey J Lister; Suzanne Brown; Stella M Resko
Journal:  Addict Sci Clin Pract       Date:  2022-07-15

3.  Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives.

Authors:  Ekaterina Pivovarova; Elizabeth A Evans; Thomas J Stopka; Claudia Santelices; Warren J Ferguson; Peter D Friedmann
Journal:  Drug Alcohol Depend       Date:  2022-03-07       Impact factor: 4.852

4.  Racial/Ethnic and Geographic Trends in Combined Stimulant/Opioid Overdoses, 2007-2019.

Authors:  Tarlise Townsend; David Kline; Ariadne Rivera-Aguirre; Amanda M Bunting; Pia M Mauro; Brandon D L Marshall; Silvia S Martins; Magdalena Cerdá
Journal:  Am J Epidemiol       Date:  2022-03-24       Impact factor: 5.363

Review 5.  Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.

Authors:  Katherine Mackey; Stephanie Veazie; Johanna Anderson; Donald Bourne; Kim Peterson
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

6.  Attitudes toward opioid use disorder pharmacotherapy among recovery community center attendees.

Authors:  Lauren A Hoffman; Corrie L Vilsaint; John F Kelly
Journal:  J Subst Abuse Treat       Date:  2021-05-08

Review 7.  Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.

Authors:  Hannah M Gregory; Veronica M Hill; Robert W Parker
Journal:  Cureus       Date:  2021-11-24

8.  Opioid Use Stigma: An Examination of Student Attitudes on Harm Reduction Strategies.

Authors:  Gemma Reynolds; Brittany L Lindsay; Stephanie Knaak; Andrew C H Szeto
Journal:  Int J Ment Health Addict       Date:  2022-01-20       Impact factor: 11.555

9.  The Relationship Between Hepatitis C Virus Rates and Office-Based Buprenorphine Access in Ohio.

Authors:  Daniel L Brook; Angela T Hetrick; Shibani R Chettri; Christine A Schalkoff; Adams L Sibley; Kathryn E Lancaster; Vivian F Go; William C Miller; David M Kline
Journal:  Open Forum Infect Dis       Date:  2021-05-17       Impact factor: 3.835

10.  Factors that influence enrollment in syringe services programs in rural areas: a qualitative study among program clients in Appalachian Kentucky.

Authors:  Umedjon Ibragimov; Katherine E Cooper; Evan Batty; April M Ballard; Monica Fadanelli; Skylar B Gross; Emma M Klein; Scott Lockard; April M Young; Hannah L F Cooper
Journal:  Harm Reduct J       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.